Abstract
[...]HF patients are divided into the following groups according to LVEF: HFrEF: symptomatic HF with LVEF ≤40%; HFmrEF: symptomatic HF with LVEF 41% to 49%; HFpEF: symptomatic HF with LVEF ≥50%; and symptomatic HF with a baseline LVEF ≤40%, a ≥10-point increase from baseline LVEF, and a second measurement of LVEF >40%. [...]only HFrEF patients have benefited from therapy recommended in the guidelines based on randomised controlled trials. Furthermore, neurohormonal activation, which is a unique feature in HF patients with reduced left ventricular systolic function, is not that prevalent among HFpEF as compared to HFrEF patients. [...]it is not surprising that the neurohormonal inhibition-oriented medication, which is effective for treating HFrEF, may fail in HFpEF patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Comprehensive Heart Failure Center, Würzburg, Germany; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany